275 related articles for article (PubMed ID: 30665944)
21. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells.
Preca BT; Bajdak K; Mock K; Sundararajan V; Pfannstiel J; Maurer J; Wellner U; Hopt UT; Brummer T; Brabletz S; Brabletz T; Stemmler MP
Int J Cancer; 2015 Dec; 137(11):2566-77. PubMed ID: 26077342
[TBL] [Abstract][Full Text] [Related]
22. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
23. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing.
Hu X; Harvey SE; Zheng R; Lyu J; Grzeskowiak CL; Powell E; Piwnica-Worms H; Scott KL; Cheng C
Nat Commun; 2020 Jan; 11(1):486. PubMed ID: 31980632
[TBL] [Abstract][Full Text] [Related]
24. Determination of a Comprehensive Alternative Splicing Regulatory Network and Combinatorial Regulation by Key Factors during the Epithelial-to-Mesenchymal Transition.
Yang Y; Park JW; Bebee TW; Warzecha CC; Guo Y; Shang X; Xing Y; Carstens RP
Mol Cell Biol; 2016 Jun; 36(11):1704-19. PubMed ID: 27044866
[TBL] [Abstract][Full Text] [Related]
25. A combinatorially regulated RNA splicing signature predicts breast cancer EMT states and patient survival.
Qiu Y; Lyu J; Dunlap M; Harvey SE; Cheng C
RNA; 2020 Sep; 26(9):1257-1267. PubMed ID: 32467311
[TBL] [Abstract][Full Text] [Related]
26. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
27. ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.
Jeong HM; Han J; Lee SH; Park HJ; Lee HJ; Choi JS; Lee YM; Choi YL; Shin YK; Kwon MJ
Oncogenesis; 2017 Oct; 6(10):e389. PubMed ID: 28991261
[TBL] [Abstract][Full Text] [Related]
28. Role of epithelial splicing regulatory protein 1 in cancer progression.
Kwon MJ
Cancer Cell Int; 2023 Dec; 23(1):331. PubMed ID: 38110955
[TBL] [Abstract][Full Text] [Related]
29. ISG15 induces ESRP1 to inhibit lung adenocarcinoma progression.
Qu T; Zhang W; Qi L; Cao L; Liu C; Huang Q; Li G; Li L; Wang Y; Guo Q; Guo Y; Ren D; Gao Y; Wang J; Meng B; Zhang B; Cao W
Cell Death Dis; 2020 Jul; 11(7):511. PubMed ID: 32641707
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
[No Abstract] [Full Text] [Related]
31. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
33. ESRP1 Induces Cervical Cancer Cell G1-Phase Arrest Via Regulating Cyclin A2 mRNA Stability.
Chen ZH; Jing YJ; Yu JB; Jin ZS; Li Z; He TT; Su XZ
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362365
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide identification and analysis of epithelial-mesenchymal transition-related RNA-binding proteins and alternative splicing in a human breast cancer cell line.
Mi Y; Dong M; Zuo X; Cao Q; Gu X; Mi H; Xiao F
Sci Rep; 2024 May; 14(1):11753. PubMed ID: 38783078
[TBL] [Abstract][Full Text] [Related]
36. N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
Liu Y; Liu R; Fu P; Du F; Hong Y; Yao M; Zhang X; Zheng S
Cell Physiol Biochem; 2015; 36(6):2494-503. PubMed ID: 26279450
[TBL] [Abstract][Full Text] [Related]
37. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.
Li J; Choi PS; Chaffer CL; Labella K; Hwang JH; Giacomelli AO; Kim JW; Ilic N; Doench JG; Ly SH; Dai C; Hagel K; Hong AL; Gjoerup O; Goel S; Ge JY; Root DE; Zhao JJ; Brooks AN; Weinberg RA; Hahn WC
Elife; 2018 Jul; 7():. PubMed ID: 30059005
[TBL] [Abstract][Full Text] [Related]
38. The pro-metastasis effect of circANKS1B in breast cancer.
Zeng K; He B; Yang BB; Xu T; Chen X; Xu M; Liu X; Sun H; Pan Y; Wang S
Mol Cancer; 2018 Nov; 17(1):160. PubMed ID: 30454010
[TBL] [Abstract][Full Text] [Related]
39. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.
Warzecha CC; Sato TK; Nabet B; Hogenesch JB; Carstens RP
Mol Cell; 2009 Mar; 33(5):591-601. PubMed ID: 19285943
[TBL] [Abstract][Full Text] [Related]
40. Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer.
Jolly MK; Preca BT; Tripathi SC; Jia D; George JT; Hanash SM; Brabletz T; Stemmler MP; Maurer J; Levine H
APL Bioeng; 2018 Sep; 2(3):031908. PubMed ID: 31069317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
